|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:2006
gptkb:European_Union
gptkb:FDA
gptkb:United_States
|
|
gptkbp:atccode
|
J05 AE08
|
|
gptkbp:available_on
|
generic drug
branded drug
|
|
gptkbp:brand
|
gptkb:Prezista
|
|
gptkbp:casnumber
|
206361-99-1
|
|
gptkbp:chemical_formula
|
C23 H31 N3 O9 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:clinical_use
|
first-line therapy
second-line therapy
treatment-experienced patients
|
|
gptkbp:contraindication
|
severe liver disease
allergy to darunavir
|
|
gptkbp:developed_by
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:dosage_form
|
oral tablet
oral suspension
800 mg once daily
600 mg twice daily with ritonavir
|
|
gptkbp:formulation
|
gptkb:tablet
suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Darunavir
|
|
gptkbp:interacts_with
|
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:rifampin
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:marketed_as
|
gptkb:Prezista
many countries
|
|
gptkbp:mechanism_of_action
|
protease inhibitor
|
|
gptkbp:pharmacokinetics
|
high bioavailability
half-life of 15 hours
metabolized by CYP3 A4
|
|
gptkbp:related_to
|
gptkb:immunotherapy
combination therapy
HIV treatment regimens
|
|
gptkbp:research_focus
|
treatment adherence
drug resistance
safety profile
long-term efficacy
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
headache
nausea
diarrhea
rash
|
|
gptkbp:storage
|
room temperature
protected from moisture
|
|
gptkbp:targets
|
HIV-1 protease
|
|
gptkbp:used_for
|
treatment of HIV
|
|
gptkbp:bfsParent
|
gptkb:TMC114
|
|
gptkbp:bfsLayer
|
6
|